Antituberculosis drug–induced hypersensitivity: clinical characteristics and risk factors
Main Article Content
Keywords
tuberculosis, drug hypersensitivity, desensitization, pyrazinamide, rifampicin
Abstract
Background: Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.
Objective: To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug–induced hypersensitivity reactions over a 10-year period in a tertiary referral center.
Methods: We retrospectively analyzed 449 patients hospitalized for antituberculosis drug–induced hypersensitivity between 2015 and 2024. A control group of 478 tuberculosis patients without hypersensitivity was included. Demographic features, comorbidities, hypersensitivity types, causative drugs, and treatment outcomes were compared.
Results: The prevalence of hypersensitivity was 12.1%. Female gender, older age, Turkish nationality, and history of other drug allergies were significant risk factors. Type 1 reactions (77.7%) were more common and associated with shorter treatment interruption and higher cure rates. Pyrazinamide was the most frequently implicated drug. Desensitization was successful in the majority of patients.
Conclusion: This large cohort study highlights key risk factors and clinical outcomes in tuberculosis drug hypersensitivity. Close monitoring of high-risk patients in the early treatment phase may reduce delays and improve outcomes.
References
2 Vega V, Cabrera-Sanchez J, Rodríguez S, Verdonck K, Seas C, Otero L, et al. Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis. BMJ Open Respir. Res. 2024 Mar 13;11(1):e002281. 10.1136/bmjresp-2023-002281
3 Liu Q, Guo D, Yu M, Tang D, Zhang Y, Luo M, et al. Clinical characteristics and risk factors for antituberculosis drug-induced hypersensitivity. Br. J. Clin. Pharmacol. 2025 Jan 91(1):134–142. 10.1111/bcp.16228
4 El Hamdouni, M., Ahid, S., Bourkadi, J.E. Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco. Infection 48; 43–50 (2020). 10.1007/s15010-019-01324-3
5 Bermingham WH, Bhogal R, Arudi Nagarajan S, Mutlu L, El-Shabrawy RM, Madhan R, et al. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs. Clin. Exp. Allergy. 2022 Mar 52(3):375–386. 10.1111/cea.14084
6 Koycu Buhari G, Oner Erkekol F, Koca Kalkan I, Ates H, Vural Solak GT, Akkale O, et al. Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations. World Allergy Organ. J. 2024 Jan 3;17(1):100862. 10.1016/j.waojou.2023.100862
7 Katran ZY, Bulut I, Babalik A, Keren M. Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug. Int. J. Mycobacteriol. 2022 Jul-Sep 11(3):309–317. 10.4103/ijmy.ijmy_78_22
8 Buhari GK, Keren M, Dursun AB, Güler M, Dulkar G, Kalaç N, et al. Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol. Ann. Allergy Asthma Immunol. 2015 Jul 115(1):39–44. 10.1016/j.anai.2015.04.015
9 Katran ZY, Bulut İ, Babalik A, Keren M. Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization. Allergy Asthma Clin. Immunol. 2022 Nov 21;18(1):97. 10.1186/s13223-022-00737-4
10 Katran ZY, Bulut İ, Babalık A, Keren M, Tepetam FM, Mersin SS, et al. Drug hypersensitivity in drug-resistant tuberculosis. World Allergy Organ. J. 2023 May 20;16(5):100778. 10.1016/j.waojou.2023.100778
11 Bulut İ, Katran ZY, Babalık A, Keren M, Tepetam FM. Delayed drug hypersensitivity to anti-tuberculosis drug: a new desensitization scheme. Postepy Dermatol. Alergol. 2024 Aug 41(4):400–407. 10.5114/ada.2024.142187
12 Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019 Jan;74(1):14–27. 10.1111/all.13562
13 Ring J and Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977 Feb 26;1(8009):466–469. 10.1016/s0140-6736(77)91953-5
14 Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br. J. Dermatol. 2007 May 156(5):1083–4. 10.1111/j.1365-2133.2007.07807.x
15 Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br. J. Dermatol. 2007 Mar 156(3):609–11. 10.1111/j.1365-2133.2006.07704.x
16 Shiohara T and Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol. Int. 2019 Jul 68(3):301–308. 10.1016/j.alit.2019.03.006
17 Ringwald M, Moi L, Wetzel A, Comte D, Muller YD, Ribi C. Risk factors for allergy documentation in electronic health record: a retrospective study in a tertiary health center in Switzerland. Allergol. Int. 2024 Jan 73(1):143–150. 10.1016/j.alit.2023.06.006
18 Kim TO, Shin HJ, Kim YI, Lim SC, Koh YI, Kwon YS. Cutaneous adverse drug reactions in patients with peripheral blood eosinophilia during antituberculosis treatment. Korean J. Intern. Med. 2019 Sep 34(5):1050–1057. 10.3904/kjim.2018.063
19 Rizzi A, Nucera E, Urbani S, Longhino D, Lohmeyer FM, Gambassi G, Krishnamra N, et al. Antituberculosis drug-induced non-blistering systemic severe reactions: a 10-year (2012-2022) literature review. Asian Pac. J. Allergy Immunol. 2023 Dec 41(4):273–291. 10.12932/AP-010423-1582
20 Modi B and Modha J. Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: a prospective study at a tertiary care centre. Indian J. Tuberc. 2022 Oct 69(4):470–475. 10.1016/j.ijtb.2021.07.018
21 Mutlu L, Bermingham WH, Mohamed OE, Melchior C, Samuel L, Heslegrave J, et al. Management of suspected hypersensitivity reactions to anti-TB drugs. Int. J. Tuberc. Lung Dis. 2023 Jul 1;27(7):570–573. 10.5588/ijtld.23.0103
22 Jani YH, Chen B, Powell N, Howard P, Sandoe J, West R, et al. Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study. J. Infect. 2025 Feb 90(2):106367. 10.1016/j.jinf.2024.106367
23 Smadhi H, Ben Saad S, Daghfous H, Ben Mansour A, Tritar F. Allergy to anti-tuberculosis treatment: place of reintroduction drug test. Tunis. Med. 2019 Mar 97(3):484–490.
24 Sim DW, You HS, Yu JE, Koh YI. High occurrence of simultaneous multiple-drug hypersensitivity syndrome induced by first-line anti-tuberculosis drugs. World Allergy Organ. J. 2021 Jul 28;14(7):100562. 10.1016/j.waojou.2021.100562
25 Kim TO, Shin HJ, Kim YI, Lim SC, Koh YI, Kwon YS. Cutaneous adverse drug reactions in patients with peripheral blood eosinophilia during antituberculosis treatment. Korean J. Intern. Med. 2019 Sep 34(5):1050–1057. 10.3904/kjim.2018.063
26 Li X, Li Y, Liu L, Wang L, Zhang L, Jiang X. Drug reaction with eosinophilia and systemic symptoms (DRESS): a retrospective study of 51 Chinese patients. Clin. Cosmet. Investig. Dermatol. 2025 Mar 4;18:525–532. 10.2147/CCID.S486550
27 Morán-Mariños C, Llanos-Tejada F, Huamani-Llantoy R, Bernal-Turpo C, López-Pilco K, Ventura-Leon A, et al. Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report. Ther. Adv. Drug Saf. 2025 Jan 24;16:20420986241312484. 10.1177/20420986241312484
28 Morán-Mariños C, Llanos-Tejada F, Salas-Lopez J, Villanueva-Villegas R, Chavez-Huamani A, Vidal-Ruiz M, et al. DRESS syndrome and tuberculosis: implementation of a desensitization and re-desensitization protocol to recover antituberculosis drugs in a case series at a specialized TB Unit in Lima, Peru. Medicine (Baltimore). 2024 Sep 27;103(39):e39365. 10.1097/MD.0000000000039365